Research · 12 min read
What a Pharmacy Benefit Manager Is, and How It Gets Paid
A company you have no contract with, never chose, and cannot call decides whether your medication is on the list, what you pay at the counter, and which pharmacy can fill it. Understanding how it earns money explains most of what looks arbitrary.
Key takeaways
- A pharmacy benefit manager builds your formulary, sets its tiers, runs the pharmacy network and utilization controls, and processes your claims.
- Federal Trade Commission staff reported that the three largest managed 79 percent of prescription drug claims for about 270 million people, and the six largest 94 percent — shares of claims, for 2023.
- Plans pay these companies through pass-through pricing with an administrative fee, or spread pricing where the company keeps the difference between pharmacy reimbursement and the plan's rate.
- Manufacturers pay them rebates in return for preferred formulary placement, plus administrative and price protection fees.
- Because those payments often reference list price, a drug with a higher sticker price and a large rebate can beat a cheaper one for a preferred slot.
- A copay claw-back is the difference between what you pay the pharmacy and what the manager reimburses it — the reason an insured copay can exceed a cash price.
- Every one of these mechanisms scales with price, which is why a high-cost category collects the most controls and the most churn.
- A January 2026 Department of Labor proposal would require disclosure of all of it to self-insured plan fiduciaries. It is proposed, not in force.
Answer first: it is a company that sits between your plan and your pharmacy
A pharmacy benefit manager runs the drug half of your health coverage. Your plan hires it, and from then on it makes most of the decisions you experience as coverage.
It builds the formulary, which is the list of drugs the plan will pay for and the tier each one sits on. It assembles the pharmacy network. It runs prior authorization and the other utilization controls. It processes the claim your pharmacy transmits.
So when a pharmacy says a drug needs prior authorization, or is not covered, or is covered only at one particular pharmacy, the rule being applied was usually written here.
The part that explains the most, and that almost nobody is shown, is how the company gets paid. It has several revenue streams, and some of them move depending on which drug ends up in the preferred position.
Nothing here says any of that is illegal or hidden. It is a business model, described in public documents by the agencies that regulate it. Knowing its shape simply makes a formulary decision less mysterious.
How much of the market this is
Federal Trade Commission staff put numbers on the concentration in an interim report published in July 2024, and the numbers explain why the answers feel standardized.
The three largest managers handled 79 percent of prescription drug claims, for approximately 270 million people. Adding the next three, the six largest managed 94 percent of prescription drug claims in the country.
Those are shares of claims processed, not shares of dollars spent, and they describe 2023. Read them as a picture of a moment rather than a permanent state.
The report also notes that concentration in a single state can run well above the national figure, and that dozens of smaller managers operate outside the largest six.
The practical meaning for you is simple. Changing jobs or plans often does not change which company writes the drug rules, because a small number of companies write most of them.
Revenue stream one: what your plan pays it
The Department of Labor described the two common shapes of this in a proposed rule published in January 2026. Compensation arrangements are sometimes grouped into pass-through pricing and spread pricing.
Under pass-through pricing, the plan pays a benchmark price minus a negotiated discount, plus an administrative fee. That fee might be charged per claim, per member, as a flat rate, or another way.
Under spread pricing, the plan pays a benchmark price with a smaller discount, and pays a reduced administrative fee or none at all. The manager instead keeps the difference between what it reimburses the pharmacy and the rate it charges the plan.
That retained difference is the spread, and it is why the second model can look cheaper on an invoice while costing more in total.
The department's own reasoning about why this is hard to evaluate is worth knowing. There is no agreed benchmark price for a given drug, the data is proprietary and costly to obtain, and managers typically do not disclose to the plan what they paid the pharmacy.
So the party paying the bill often cannot verify the number on it. That is the problem the proposed rule is aimed at.
Revenue stream two: what drug manufacturers pay it
This is the stream that shapes formularies, and the department described it directly.
Rebates, in its words, are discounts on drugs offered by the manufacturer in return for preferred placement on a plan's formulary. Whether the manager keeps a rebate or passes it to the plan is a matter of contract between them.
Administrative fees from manufacturers are a second piece, earned when prescriptions are filled. Price protection fees are a third — an additional rebate paid if a list price rises faster than inflation or another agreed measure.
Then comes the sentence that explains the whole complaint. These payments are often defined by reference to list price, which commenters allege gives managers an incentive to choose drugs with a high list price and a high rebate when building a formulary.
Follow that through and a familiar frustration stops looking random. A drug with a lower sticker price and no rebate can lose a formulary slot to one with a higher sticker price and a large rebate.
The department also notes that rebate negotiation has increasingly moved into affiliated group purchasing organizations, sometimes called rebate aggregators. Each of the three largest managers is part of a vertically integrated business that owns such a subsidiary.
Revenue stream three: the one that happens at your counter
The proposed rule names a practice most people have never heard of and some have experienced.
A copay claw-back is the department's term for the difference between the copayment or coinsurance you hand the pharmacy and what the manager actually reimburses that pharmacy. Where the manager recoups part of that difference, it becomes compensation.
There is nothing to claw back when the pharmacy's reimbursement exceeds your copayment. The practice only exists in the other direction.
This is the mechanism behind an experience people find impossible to believe. Your insured copay can be higher than the price the pharmacy would have charged you without insurance.
It is also the reason asking the pharmacist for the cash price is a reasonable question rather than a rude one. On some fills it is genuinely lower, and the only way to know is to ask.
Be aware of the tradeoff before you switch. Paying cash outside your plan generally earns you no credit toward your deductible or out-of-pocket maximum, because there is no claim for the plan to process.
Why this matters more for a GLP-1 than for a generic
Every mechanism above scales with price. On a low-cost generic the amounts involved are small enough that the incentives barely register.
On a high-cost, high-demand category, the same mechanisms move real money, and the pressure on formulary placement and utilization controls rises with it.
That is a large part of why this category collects so many prior authorization requirements, quantity limits, and preferred-product rules. The controls are not a judgment about you.
It also explains the churn. Preferred placement follows contracts, and contracts get renegotiated, so a drug that was covered in one plan year can move tiers or leave the list in the next.
None of this changes what your prescriber thinks you should take. It changes which version of that decision the plan will pay for, and how often that answer is revisited.
What is being proposed, and what has not happened yet
In January 2026 the Department of Labor published a proposed rule on pharmacy benefit manager fee disclosure. It is a proposal. Nothing in it is in force.
What it would require is disclosure to the people running self-insured employer plans, which are governed by the federal law covering employee benefit plans. Those plan fiduciaries have a legal duty to judge whether what they pay a service provider is reasonable.
The proposed disclosures track the revenue streams above. Direct compensation, payments from drug manufacturers, spread compensation, copay claw-backs, compensation for terminating a contract, and formulary placement incentives each get their own requirement.
The stated purpose of the formulary provision is the useful one to remember. It is meant to help a plan fiduciary evaluate the manager's formulary selections and how those selections might be influenced by incentives, arrangements, and payments.
Read that as an official acknowledgment that the influence is real enough to be worth measuring. Whether the rule is finalized, changed, or dropped is a separate question with no answer yet.
Watch the outcome rather than the proposal. A proposed rule shows what an agency is considering, and only a final rule changes what applies.
What you can actually do with this
Find out who administers your drug benefit, because it is frequently not the company on your medical card and it often has its own phone number and portal.
Get the formulary and the published coverage criteria for the drug class from that company, not from a general benefits summary. The criteria document is what a decision is measured against.
Ask the pharmacy for the cash price on a fill, and compare it against your copay. Do the comparison knowing that cash spending usually earns no credit toward your plan totals.
If your coverage comes through a self-insured employer, questions about the contract belong with your benefits team rather than the administrator. They are the ones with a fiduciary duty and the ones who can ask for terms.
When a drug moves tiers or leaves the list, ask whether a formulary exception process exists and what it requires. That is a defined process in most plans, separate from an appeal of a denial.
Keep the two questions apart. What should I take is for your prescriber. What will be paid for, and on what terms, is a benefit question with a paper trail you are entitled to read.
Sources
- Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (proposed rule, document 2026-01907)The two compensation models, pass-through pricing and spread pricing, and why spread pricing is hard for a plan to evaluate. Also the description of manufacturer payments — rebates in return for preferred formulary placement, administrative fees, and price protection fees — and the allegation that referencing list price rewards high-list, high-rebate drugs. Also the definition of a copay claw-back, the move of rebate negotiation into affiliated group purchasing organizations, and the proposed disclosure categories including formulary placement incentives. This document is a proposal and is described as one throughout.
- Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies (Interim Staff Report)The concentration figures: the three largest managing 79 percent of prescription drug claims for approximately 270 million people, and the six largest managing 94 percent, stated for 2023. Also that a single state's concentration can far exceed the national share, and that dozens of smaller managers operate outside the largest six.
Frequently asked questions
What is a pharmacy benefit manager, in one sentence?
It is a company your health plan hires to run the drug side of your coverage. It builds the formulary and its tiers, assembles the pharmacy network, operates prior authorization and other utilization controls, and processes the claims your pharmacy transmits. You have no contract with it and did not choose it, but most of what you experience as drug coverage is its work. It is also frequently a different company from the one whose logo is on your medical card, which is why a medical member services line often cannot answer a medication question.
Why would a cheaper drug lose to a more expensive one on the formulary?
Because of how the manager is paid by manufacturers. The Department of Labor described rebates as discounts offered by a manufacturer in return for preferred placement on a formulary. It noted that such payments are often defined by reference to list price. Commenters allege that this gives managers an incentive to choose drugs with a high list price and a high rebate when building the list. A drug with a lower sticker price and no rebate can therefore lose a preferred slot. Whether a rebate reaches your plan at all is a matter of contract between the plan and the manager.
How can my copay be higher than the cash price?
Through a mechanism the proposed federal rule calls a copay claw-back. It is the difference between the copayment or coinsurance you pay the pharmacy and what the manager reimburses that pharmacy. Where the manager recoups part of that difference, the money becomes its compensation. Nothing is clawed back when the pharmacy's reimbursement is larger than your copayment, so the practice only runs one direction. This is why asking a pharmacist for the cash price is worth doing. Just know that paying cash outside your plan generally earns no credit toward your deductible or out-of-pocket maximum.
What is spread pricing?
It is one of two common ways a plan pays its pharmacy benefit manager. Under pass-through pricing, the plan pays a benchmark price minus a negotiated discount, plus a separate administrative fee. Under spread pricing, the plan pays a benchmark price with a smaller discount, and a reduced administrative fee or none. The manager then keeps the difference between what it reimburses the pharmacy and what it charges the plan. That retained difference is the spread. The Department of Labor noted that it is hard for a plan to evaluate, because there is no agreed benchmark price and managers typically do not disclose what they paid the pharmacy.
Are these companies required to tell my employer what they earn?
That is exactly what was proposed in January 2026, and it is a proposal rather than a rule in force. The Department of Labor put forward disclosure requirements aimed at people running self-insured employer plans, who have a legal duty to judge whether a service provider's compensation is reasonable. The proposed disclosures cover direct compensation, payments from drug manufacturers, spread compensation, copay claw-backs, termination compensation, and formulary placement incentives. Whether it is finalized, amended, or dropped has no answer yet. Treat any claim that these disclosures are now required as premature.
Does any of this change what my prescriber recommends?
No. It changes which version of that recommendation your plan will pay for, and how often the answer gets revisited. A formulary decision is a payment decision, and your prescription remains valid regardless of where a drug lands on a list. What the mechanics do explain is the churn — preferred placement follows contracts, contracts get renegotiated, and a drug covered in one plan year can move tiers or leave the list in the next. If that happens, ask whether your plan runs a formulary exception process, which is a defined route separate from appealing a denial.